Psoriasis Clinical Trials

• Male or female subjects aged 18-75 years (inclusive)

• Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomization.

• Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Static Physician Global Assessment (sPGA) score \>=3.

• Subjects who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator

• Subjects who are able to use effective contraception from the screening period to 6 months after the last dose